Australia's regulator looks increasingly isolated after the European Union approved Eisai and Biogen's monoclonal antibody LEQEMBI (lecanemab) for early Alzheimer's Disease.
Australia increasingly isolated after Europe approves Alzheimer's therapy
April 22, 2025 BioPharmaLatest News
Latest Video
New Stories
-
Pharmac proposes three-monthly quantities for popular asthma inhalers
April 22, 2025 - - Latest News -
Lilly records another win in weight loss in trial of oral GLP-1 agonist
April 22, 2025 - - Latest News -
Australia increasingly isolated after Europe approves Alzheimer's therapy
April 22, 2025 - - BioPharma -
FDA removes industry representatives from its advisory committees
April 22, 2025 - - Latest News -
'Arguing over the proverbial lifejacket whilst patients are in the water drowning. Shame'
April 22, 2025 - - Latest News -
A mixed bag for the industry in Trump executive order on medicine pricing
April 17, 2025 - - Latest News -
Telix says IPAX-Linz study shows promising efficacy for glioma therapy candidate
April 16, 2025 - - Australian Biotech